85 results on '"Punt, C."'
Search Results
2. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study
3. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
4. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
5. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case–control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy
6. O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
7. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial†
8. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
9. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
10. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer
11. O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors
12. SO-30 Adjuvant systemic chemotherapy versus active surveillance following upfront resection of isolated synchronous colorectal peritoneal metastases: Propensity score-matched analysis of a nationwide registry
13. LBA-6 Safety, feasibility, tolerability, and preliminary efficacy of perioperative systemic therapy for resectable colorectal peritoneal metastases: Pilot phase of a randomised trial (CAIRO6)
14. P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens
15. SO-19 S-1 is a cost-effective alternative to capecitabine in metastatic colorectal cancer
16. P-275 Quality of life and symptoms in patients undergoing CRS-HIPEC with or without perioperative systemic treatment for colorectal peritoneal metastases: Results from the randomised CAIRO6 trial
17. The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab
18. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
19. A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer
20. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
21. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer
22. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
23. Chemotherapy response evaluation with FDG–PET in patients with colorectal cancer
24. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma
25. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
26. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
27. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
28. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
29. Phase II study of E7070 in patients with metastatic melanoma
30. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results
31. New options and old dilemmas in the treatment of patients with advanced colorectal cancer
32. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
33. Adjuvant interferon for melanoma
34. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study
35. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer
36. Adjuvant interferon-alpha for melanoma revisited: News from old and new studies
37. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)
38. The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC Melanoma Group
39. 'Hold the Mayo': Solid facts or pulp fiction?
40. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis
41. Copy number alterations as predictive biomarkers for response to bevacizumab in metastatic colorectal cancer
42. Evolution of skeletal muscle mass (SMM) during palliative systemic treatment in metastatic colorectal cancer (mCRC) patients participating in the randomized phase 3 CAIRO3 study
43. Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials
44. O-022 - Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis
45. Impact of Baseline Covariates and Prior Therapy on the Efficacy of Second-Line Panitumumab (Pmab) + Folfiri Vs Folfiri Treatment
46. KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis
47. 594P - Evolution of skeletal muscle mass (SMM) during palliative systemic treatment in metastatic colorectal cancer (mCRC) patients participating in the randomized phase 3 CAIRO3 study
48. 463PD - Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials
49. 548P - Impact of Baseline Covariates and Prior Therapy on the Efficacy of Second-Line Panitumumab (Pmab) + Folfiri Vs Folfiri Treatment
50. PD-0002 - KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.